By Lew Kizer — 2026-10-21 — Health & Nutrition
The short answer
On October 16, 2026, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) recommended approval of Eli Lilly's Foundayo (orforglipron), a once-daily oral GLP-1, for weight management and type 2 diabetes in adults. The European Commission will make the final decision. Foundayo launched in the United States in April 2026.
Key facts
- CHMP recommendation: Oct. 16, 2026, for weight management and type 2 diabetes in adults.
- The European Commission must still issue final approval.
- Second oral obesity drug backed by the EMA committee, after Novo Nordisk's Wegovy pill.
- Foundayo launched in the U.S. in April 2026.
- The recommendation does not change U.S. availability or prescribing.
KINGSPORT, Tenn., Oct. 21, 2026 — The oral version of a GLP-1 weight-loss medicine took another step toward a much larger market last week.
On October 16, the EMA's Committee for Medicinal Products for Human Use recommended approval of Eli Lilly's Foundayo (orforglipron) for weight management and for type 2 diabetes in adults.
This article reports research news and is not medical advice. Talk with your clinician before changing your diet or medicines.
What happened and what is next
| Step | Status |
|---|---|
| U.S. launch | April 2026 |
| EMA committee (CHMP) opinion | Positive, Oct. 16, 2026 |
| European Commission decision | Pending |
Foundayo is the second oral obesity drug to win the committee's backing, after Novo Nordisk's Wegovy pill. A positive CHMP opinion is usually followed by a Commission decision, but approval is not final until it is issued.
Why U.S. patients should care
Nothing changes at a U.S. pharmacy because of a European opinion. What it does signal is that daily pills are becoming a mainstream option alongside weekly injections. Our Foundayo food guide covers how people on the pill can plan meals around a smaller appetite.
The food side does not change
“When you're on a GLP-1 medication, what you eat matters more, not less. You need high-protein, portion-controlled, nutrient-dense food — and you need to know it's safe. That's exactly what we do.” — Lew Kizer, Founder, SmashMeals
See our GLP-1 meal planning page or order this week's meals.
Commentary, not medical advice
The SmashMeals perspective
Pills make these medicines easier to start, and that means more people will be eating smaller amounts of food for a long time. Whatever form the medicine takes, the plate still has to carry protein, fiber and enough real nutrition. That part has not changed, and it is the part we cook for.
Frequently asked questions
Is Foundayo approved in Europe?
Not yet. On October 16, 2026, the EMA's CHMP recommended approval. The European Commission makes the final decision.
Is Foundayo available in the United States?
Yes. Foundayo (orforglipron) launched in the U.S. in April 2026. Ask your prescriber whether it fits you.
Do I need to eat differently on a GLP-1 pill?
Follow the instructions on your prescription. In general, people on GLP-1 medicines eat less, so protein, fiber and nutrient-dense foods matter more. A registered dietitian can help set targets.
Sources and credits
Follow the original sources for context and verification. A reference is not an endorsement of SmashMeals.
- European Union regulators recommend approval for Eli Lilly weight loss pill (opens in a new tab)
Yahoo Finance
Why it matters: Reports the recommendation, indications and next step.
- Eli Lilly's weight-loss pill wins EU drug regulator's backing (opens in a new tab)
CNBC
Why it matters: Same-day coverage of the CHMP opinion.